Zentiva a.s.
BBSSE:1SKF401E33.20
EUR
+2.20
(+7.10%)
ISIN
SK1120004439
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Bratislava Slovakia
- IPO Date
- May 1, 2008
- Similar Companies
- Business
- Zentiva a.s. is a pharmaceutical company that develops, manufactures, markets, and distributes generic prescription medicines, over-the-counter healthcare products, and active pharmaceutical ingredients. The company offers a wide portfolio of pharmaceuticals across key therapeutic categories, including cardiovascular diseases, comprising antihypertensives, lipid-lowering agents, and antiarrhythmics; central nervous system disorders, comprising antidepressants, anxiolytics, antiepileptics, and analgesics; gastrointestinal and metabolic conditions, comprising oral antidiabetics and proton pump inhibitors; respiratory diseases, comprising bronchodilators, antihistamines, and inhaled formulations; anti-infectives, comprising broad-spectrum antibiotics and antifungals; oncology and supportive care therapeutics; pain management and anti-inflammatory treatments; and urological medications. In addition to prescription drugs, the company provides over-the-counter consumer health solutions, food supplements, and specialized contract development and manufacturing organization services to third-party pharmaceutical partners. Tracing its historical origin to the Black Eagle pharmacy founded in 1488 and operating in its modern corporate form since 1998, Zentiva a.s. is headquartered in Prague, Czech Republic, and operates as a standalone company under the ownership of private equity firm Advent International. The company conducts commercial operations across Europe, the Middle East, and Africa, supported by primary manufacturing centers in Prague, Czech Republic; Bucharest, Romania; and Ankleshwar, India. In recent corporate developments, Zentiva has accelerated its geographic and portfolio expansion through the acquisition and integration of Alvogen's Central and Eastern European business and Romanian pharmaceutical company Solacium Pharma, alongside the strategic acquisition of the Ankleshwar manufacturing site. The company has also expanded its therapeutic pipeline through commercialization partnerships for biosimilars and value-added generic formulations, while executing major capital expenditure programs to expand oral solid dosage, packaging, and high-potency manufacturing capacities across its European production network.